Louisiana Cannabis: A Two-Producer Monopoly with 12% Capture, $8.50+/g Floor Pricing, and a Program That Prices Out Its Heaviest Patients

Louisiana's medical cannabis program runs on just two licensed producers supplying a hard-capped 30 dispensaries statewide. Wholesale distribution to pharmacies reached an estimated $90.9 million in the year ending June 2025 — a figure independently confirmed two ways, once by state tax collections and once by industry reporting. Against roughly 150,000 registered patients, the legal channel covers an estimated 48% of expected patient demand. But that number understates the real story: menu pricing rarely dips below $8.50 a gram even at its cheapest, and at that floor a two-gram-a-day patient is paying more than $500 a month — a cost structure that likely prices out the heaviest, highest-need consumers rather than serving them.

Market Overview

Louisiana legalized therapeutic marijuana in 1978, but the program existed in name only until 2015, when the legislature began meaningful implementation. The first legal sales began in August 2019. Regulatory authority over retail sites shifted from the Louisiana Board of Pharmacy to the Louisiana Department of Health (LDH) on January 1, 2025.

The market's defining structural feature is supply concentration: only two licensed producers — Ilera Holistic Healthcare and Good Day Farm Louisiana — grow and process all cannabis sold in the state. State law caps retail at 30 dispensaries (still called "pharmacies" in Louisiana), spread across nine mandated regions; 27 were operating as of late 2025. That's a duopoly on the supply side and a hard ceiling on the retail side — a combination that shows up directly in price.

Key metrics:

• ~$90.9M in wholesale distribution (producer to pharmacy), fiscal year ending June 30, 2025 — up 77% year over year, confirmed independently via Louisiana Department of Revenue's Therapeutic Marijuana Fee collections
• ~26.3M grams estimated flower-equivalent volume distributed (derived from state production-report weight data)
• ~$3.46/g implied wholesale price (wholesale $ ÷ estimated volume)
• Menu pricing rarely below ~$8.50/g at retail, even at the cheapest observed pricing — a floor, not a typical price
• ~150,000 registered patients (early 2026), more than doubling in under two years
• ~48% estimated capture against patient-based demand
• 27 operating dispensaries (30-license hard cap), ~0.8 per 100,000 adults 21+
• 7% state tax on retail medical cannabis sales
• Adults 21+: ~3.3 million (Census Bureau, ~4.6M total population, July 2025)

Flower Pricing

Louisiana's Act 150 production report gives a rare, directly measured wholesale volume figure: Ilera distributed 2,041,200 grams of flower to pharmacies in 2025, and Good Day Farm distributed 11,219,000.5 grams — 13.26 million grams of flower combined. Neither company's report includes price, so the volume side and the dollar side come from different sources, but they line up. Good Day Farm's blended ratio of flower-to-total-units, applied to Ilera's reported non-flower unit count, extends the flower figure to an estimated 26.3 million grams of total flower-equivalent volume for the state.

Set against the Louisiana Department of Revenue's ~$90.9 million wholesale figure for the same period, that implies a wholesale price near $3.46 per gram — plausible for a producer-to-pharmacy transaction. What patients actually pay is a different number entirely. Menu sampling across Louisiana pharmacies found it difficult to locate an eighth (3.5g) under $30 — a ~$8.57/g floor, and that was the lowest price found, not a typical one. With only two producers and a fixed 30-store ceiling, there is no competitive pressure pushing prices toward the commodity floor seen in oversupplied adult-use markets. The wholesale-to-retail markup — roughly 2.5x at the floor, likely higher in practice — reflects dispensary margin, the 7% state tax, and until recently, the outsized federal tax burden of IRC §280E.

Tax Structure

Louisiana applies a 7% state sales tax on retail medical cannabis sales — a modest rate by national standards. The more consequential tax story in 2025 wasn't the state rate; it was federal. Until the DEA's rescheduling action, Louisiana's cannabis businesses — like all others nationally — were subject to IRC §280E, which barred standard business-expense deductions and pushed effective federal tax rates as high as 70% for cannabis operators. State-licensed medical operators are now eligible for relief from §280E, subject to the new DEA registration and compliance process — the change doesn't legalize cannabis federally, but it does let registered dispensaries deduct rent, payroll, marketing, and equipment costs for the first time, a meaningful cost reduction that industry sources expect to eventually show up in retail pricing.

Separately, a 15% wholesale excise tax (HB 636) takes effect January 1, 2026 — but it explicitly exempts medical marijuana obtained under Louisiana's existing therapeutic program. It's aimed at the adult-use market Louisiana doesn't yet have, not the medical channel this analysis measures. Worth watching if Louisiana legalizes adult-use, but it won't touch the pricing described here.

Total Addressable Market

Louisiana patients access medical cannabis through a physician recommendation rather than a traditional state-issued medical card. Since the program broadened physician discretion, the practical gate is a doctor's judgment call, not a fixed list of qualifying conditions or the open self-certification seen in Oklahoma or DC. That makes the standard framework baseline (18% adult participation) the wrong comparison; measuring Louisiana against a hypothetical fully-open adult-use population overstates what the program was ever built to serve. The more honest denominator is the state's own registered patient base.

• ~150,000 registered patients (early 2026, enrolled/recommended — Louisiana has no traditional ID-card registry, so this counts patients with an active physician recommendation, not necessarily active monthly purchasers), against ~3.3 million adults 21+ — a 4.5% participation rate
• At the framework's 1.0 gram/day baseline, patient-level demand runs ~54.8 million grams annually
• Against the estimated 26.3 million grams of legal volume, that's ~48% estimated capture

Louisiana's estimated legal capture against total demand (medical & adult use): 12%.

This is a modeled figure resting on two stacked assumptions: the GDF-ratio extension used to estimate total flower-equivalent volume (see Flower Pricing), and the framework's 1.0 g/day patient consumption baseline. That baseline is, if anything, conservative here — Louisiana caps patient purchases at 71 grams per 14 days, or roughly 5 grams a day, well above the framework's assumed rate. Read the capture rate directionally, not as a precise measurement.

The 48% figure also obscures more than it reveals about who the legal channel is failing to serve. A patient consuming a gram or less a day faces a manageable cost at Louisiana's pricing. A patient consuming two grams a day or more — the population capture statistics are least likely to reach — is paying well above $500 a month at even the lowest observed pricing. That's a cost structure few patients can sustain long-term through a licensed pharmacy, and it points toward the illicit market or reduced consumption rather than full legal-channel reliance. Louisiana's capture problem isn't evenly distributed across patients; it concentrates hardest on the heaviest, highest-need consumers.

Revenue Trend

Wholesale distribution to pharmacies grew from an estimated $51.4 million (FY2024, back-calculated from the prior year's Therapeutic Marijuana Fee collections) to $90.9 million in FY2025 — a 77% single-year increase. Patient registrations tell the same growth story from a different angle: the program more than doubled its enrolled patient base in under two years, reaching roughly 150,000 by early 2026. Both curves point to a market still in its steep growth phase, not yet at the plateau seen in more mature medical programs like Missouri's or Mississippi's.

Dispensary Density

Louisiana's 27 operating dispensaries against roughly 3.3 million adults 21+ produce a density of ~0.8 per 100,000 — among the lowest of any market in this framework, a direct consequence of the state's 30-license hard cap.

*Louisiana's revenue/store reflects wholesale distribution, not retail sales, and isn't directly comparable to the retail-derived figures shown for other states.

The license cap keeps density near the bottom of the framework regardless of demand growth — new patients have nowhere to go but the same 27 (soon, at most, 30) stores, which is part of why pricing has stayed elevated even as the patient base has more than doubled.

Home Cultivation

Louisiana permits no home cultivation of any kind, for patients or otherwise — one of the stricter positions in the medical-cannabis landscape. Combined with the retail price floor, this leaves patients with no legal alternative to purchasing through the two-producer, 27-pharmacy system at whatever price it sets.

The Bottom Line

Louisiana's cannabis market is a study in what happens when supply is deliberately kept scarce on both ends of the chain. Two producers and a 30-dispensary cap mean there's never been meaningful price competition, and the result shows up exactly where you'd expect: a retail floor near $8.50 a gram, no home-grow alternative, and a legal capture rate that likely looks much better for occasional patients than for the heaviest consumers the program is supposed to serve.

The two confirmations of the $90.9 million wholesale figure — once through industry reporting, once through the state's own Therapeutic Marijuana Fee collections — give this analysis a firmer footing than most medical-only markets, where a single unverified number often has to carry the whole piece. What happens next depends less on new taxes, since the medical channel is exempt from the incoming adult-use excise, and more on whether rescheduling's 280E relief for dispensaries actually translates into retail prices patients can sustain.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.